Valortim

PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)

...s funding will be used to support further study of valortim in a promising new animal model of anthrax infecti...thew G. Meldorf, M.D., Senior Program Director for valortim at PharmAthene. The new model, which is being deve...e accurately determine the therapeutic efficacy of valortim in animals who have active disease defined in this...

Valortim in Medical Technology

Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection

Pilot Study Demonstrates 50% Survival in Valortim-Treated Animals PRINCETON, N.J. and ANNAPOLIS, Md., March 29, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc. , a leading monoclonal antibody company, and PharmAthene, Inc., a privately held biotechnology company dedicated to the development...

Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology

... with Drs. Cross and Basu to better characterize these intriguing results. valortim (R) has demonstrated efficacy in non-clinical studies as well as favorable safety data collected from our Phase I clinical study. We believe that valortim (R) may have important competitive advantages, including a novel mechanism...

Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection

... the rapid assay, animals were administered either valortim or saline (control) by intravenous injection. In t... in which to determine the therapeutic efficacy of valortim in animals confirmed to have active disease. We be... rabbit animal model had suggested the capacity of valortim to successfully treat symptomatic animals," noted ...

Valortim in Biological Technology

PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting

...ous Disease, National Institutes of Health. valortim (R) PK Findings Reported Pharmacokinetic da... challenge of the anthrax Ames strain. About valortim (R) Valortim(R) is a fully human monoclonal a...oms become evident). As previously presented, valortim has been administered intravenously and intramuscu...

Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)

...ection, further defining the potential efficacy of valortim in anthrax disease," commented Dr. Lowy. "Animal m..., supporting the accuracy of the approach and that valortim had impressive activity in this setting. This stud... inhalation disease, and to assess the efficacy of valortim in this model. In the study, 32 adult NZW rabbits ...

PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations

...uct development will help to ensure the success of valortim (TM) and Protexia(R), our biodefense product candi...ents, respectively." Mr. Wright continued, "Both valortim and Protexia continue to make excellent progress. ...00L engineering run. If successful, it will enable valortim to be positioned for procurement by the U.S. gover...